Jim Cramer Talked About These 11 Stocks Recently

9. Merck & Co., Inc. (NYSE:MRK)

Cramer mentioned that drug stocks like Merck & Co., Inc. (NYSE:MRK) are hated in the market these days and said:

“Right now, the drug stocks… are despised beyond all belief, just drop-dead despised. There seems to be no price where they’re safe. They are hated. We’re hearing that Robert F. Kennedy, Jr., big vaccine denier, will get appointed as the Secretary of Health and Human Services, which is definitely bad for Big Pharma. Maybe that’s why they’ve been going down so hard but these stocks have already been hit. I think that the hatred is almost priced in, except for the stocks of companies that sadly make vaccines. Robert F. Kennedy Jr. has not been a big fan of the vaccines, to say it mildly. Merck, with a great stable of cancer drugs, now sells for just over 10 times next year’s earnings… But these stocks are trading like Bernie Sanders just won the election on a platform of socialized medicine. These stocks are just way too hated.”

Merck (NYSE:MRK) is a leading global healthcare company focused on the research, development, and commercialization of a broad spectrum of pharmaceutical products. Its pipeline of drug development programs remains expansive, including dozens of ongoing initiatives aimed at addressing unmet medical needs.

This pipeline has been further strengthened through strategic acquisitions, such as the purchase of Acceleron Pharma in 2021. This acquisition led to the approval of Winrevair, a new treatment for pulmonary arterial hypertension.

Additionally, in the third quarter, the company acquired an innovative investigational bispecific T-cell engager from Curon, which has potential applications in both oncology and immunology, aligning with its ongoing efforts to address critical unmet needs in these fields. Merck (NYSE:MRK) has revised its full-year sales forecast to a range of $63.6 billion to $64.1 billion. The company also expects its full-year non-GAAP EPS to fall between $7.72 and $7.77.